Table 2.
Study progress for nanobodies or single-domain antibodies in preclinical and clinical trials (data sources for clinical trials: https://clinicaltrials.gov/, accessed on 9 August 2022).
| Rank | NCT Number | Title | Phases |
|---|---|---|---|
| 1 | NCT03224702 | First-in-Human Trial of Anti-ADAMTS-5 Nanobody in Healthy Volunteers | Phase 1 |
| 2 | NCT03583346 | Multiple Ascending Doses (MAD) of Anti-A Disintegrin and Metalloproteinase With Thrombospondin Motifs-5 (Anti-ADAMTS-5) Nanobody in Participants With Knee Osteoarthritis (OA) | Phase 1 |
| 3 | NCT02156466 | Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects | Phase 1 |
| 4 | NCT03881761 | CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma | Phase 1 |
| 5 | NCT01151423 | Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) | Phase 2 |
| 6 | NCT04489862 | αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors | Early Phase 1 |
| 7 | NCT01374503 | First in Man Study of ALX-0651, a Nanobody Inhibiting CXCR4 | Phase 1 |
| 8 | NCT01284569 | Study to Assess Safety and Efficacy of Anti-Interleukin 6-receptor (IL6R) Nanobody in Rheumatoid Arthritis (RA) Patients | Phase 1|Phase 2 |
| 9 | NCT03664661 | BCMA-CAR-T in Relapsed/Refractory Multiple Myeloma | Phase 1 |
| 10 | NCT01259765 | Llama Antibody, Rotavirus Diarrhoea, Children | Phase 2 |
| 11 | NCT04469725 | KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma | Phase 2 |
| 12 | NCT04126590 | Phase I Study of KN044 in Locally Advanced/Metastatic Solid Tumors | Phase 1 |